Imaging Biometrics Ltd on Thursday noted the use of its Functional Tumor Burden mapping technology in a glioblastoma clinical trial at Cooper University’s MD Anderson Cancer Center.
The London-based healthcare imaging software firm said the US university’s phase 2 feasibility study is exploring a ‘novel treatment paradigm’ for patients with newly diagnosed high grade gliomas: administering temozolomide chemotherapy prior to radiation therapy.
‘IB’s FTB maps will provide voxel-level classification of tumor tissue based on perfusion characteristics, distinguishing active tumor from necrosis and treatment-related changes - a critical distinction that conventional imaging often fails to make,’ the company said.
‘By comparing baseline and post-treatment FTB maps, deeper insights will be gained into tumor response trajectories and the biological impact of early chemotherapy - particularly in MGMT methylated tumors, which are known to respond more favorably to temozolomide,’ it added.
IB said the approach aims to determine whether early objective response rates-measured before radiation-can serve as reliable surrogates for drug activity.
‘If validated, this paradigm could revolutionize early-phase clinical trial design in neuro-oncology, enabling more efficient drug screening and personalized treatment strategies,’ IB said.
Shares closed up 5.6% at 0.95 pence each in London on Thursday, for a market cap of £4.2 million. Shares are down 14% over the last year.
Copyright 2025 Alliance News Ltd. All Rights Reserved.
